Abstract
It has been known for a long time that vitamins are essential nutrients for humans and animals. These substances are important for regular cell function, growth and development. Relatively small amounts of vitamins are needed to perform vital functions. As a rule vitamins promote the actions of enzymes in order to improve its efficiency and in this role they are called coenzymes.
There are 13 essential vitamins vitamin A, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B3 (niacin), pantothenic acid, biotin, vitamin B6 (pyridoxine), folate (folic acid, vitamin B9), vitamin B12, vitamin C, vitamin D, vitamin E, and vitamin K, which are needed for normal functioning of mammalians’ life.
Normal neurosystem functioning depends on its structural and functional perfection. During life, the human body is exposed to many elements, which create free radicals. These free radicals are known to date as distractive agents for many biological systems include the neurosystem. Free radicals are atoms or groups of atoms with unpaired number of electrons and can be formed when oxygen interacts with certain molecules. Once these highly reactive radicals are formed, they can start a chain reaction – “domino effect”, which produces membranes damage. To prevent this damage, the body has an antioxidation defense system. Antioxidants are molecules, which can safely interact with free radicals and terminate the chain reaction before vital molecules are damaged. Antioxidative agents are intimately involved in the prevention of cellular damage – the common pathway for cancer, aging, and a variety of diseases. The antioxidant defense system is important in maintaining cellular homeostasis and preventing oxidative stress.
According to the present invention, antioxidants like vitamins and other antioxidative agents may be considered as further active components because antioxidants inhibit free radical distractive activities. Antioxidants, especially lipid-soluble antioxidants, can be absorbed into the cell membrane to neutralize oxygen radicals and thereby protect the membrane.
Although there are several enzyme systems within the body that scavenge free radicals, the principle vitamin antioxidants are vitamin E, beta-carotene, vitamin C and vitamins from the B group.
Vitamins C, E and K are known to protect neurons from oxidative damage in stroke and in other neurodegenerative conditions. B vitamins are critically important in maintaining the normal functions of the brain. Deficiency in B vitamins results in a predictable sequence of different neurological and psychiatric disturbances.
This chapter is focused on evidence from clinical and basic science studies supporting a role of several vitamins as potential neuroprotective compounds. Neuroprotective effects of them as add-on therapies merit further investigations in schizophrenia and mood disorders.
With the progress of understanding the illnesses’ reasons, it becomes clearer that to prevent maladies is much easier, than to treat them.
(I.I. Mechnikoff)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- AD:
-
Alzheimer’s Disease
- ADHD:
-
Attention Deficit Hyperactivity Disorder
- ATP:
-
Adenosine Triphosphate
- BARS:
-
Barnes Akathisia Rating Scale
- BPRS:
-
Brief Psychiatric Rating Scale
- CNS:
-
Central Nervous System
- CSF:
-
Cerebrospinal Fluid
- DFE:
-
dietary folate equivalent
- 7-DHC:
-
7-dehydrocholesterol
- DNA:
-
Deoxyribonucleic Acid
- GABA:
-
Gamma-Aminobutyric Acid
- 5-HT:
-
Serotonin
- L-5HTP:
-
L-5-hydroxytryptophan
- IU:
-
International Unit
- LT:
-
Lithium-Induced Tremor
- mcg:
-
micrograms
- MRI:
-
Magnetic Resonance Imaging
- MRS:
-
Magnetic Resonance Spectroscopy
- NIA:
-
Neuroleptic-Induced Akathisia
- NIH:
-
National Institutes of Health
- nM/L:
-
Nanomoles per Liter
- NMDA:
-
N-methyl-D-aspartic Acid
- PANSS:
-
Positive and Negative Syndrome Scale
- PD:
-
Parkinson’s Disease
- PLP:
-
Pyridoxal 5′-Phosphate
- PSNL:
-
Partial Sciatic Nerve Ligation
- RAE:
-
Retinol Activity Equivalents
- RDA:
-
Recommended Dietary Allowance
- RNA:
-
Ribonucleic Acid
- SAS:
-
Simpson-Angus Scale
- SGAs:
-
Second Generation Agents
- SNCI:
-
Sciatic Nerve Crush Injury
- SSRIs:
-
Selective Serotonin Reuptake Inhibitors
- TD:
-
Tardive Dyskinesia
- TH:
-
Thermal Hyperalgesia
- t.i.d.:
-
three times a day
- TMP:
-
Thiamin Monophosphate
- TTP:
-
Thiamin Triphosphate
- TPP:
-
Thiamin Pyrophosphate
- U.S.:
-
United States of America
- USDA:
-
United States Department of Agriculture
- UVB:
-
Ultraviolet-B
References
Carpenter KJ. A short history of nutritional science: part 2 (1885–1912). J Nutr 2003; 133:975–984
Rosenfeld L. Vitamine – vitamin. The early years of discovery. Clin Chem 1997; 43:680–685
Carpenter KJ. A short history of nutritional science: part 3 (1912–1944). J Nutr 2003; 133:3023–3032
Zempleni J, Rucker RB, Suttie JW, McCormick DB (eds) Handbook of Vitamins, 4th ed. CRC Press, Boca Raton, FL; 2007
Combs GF. The Vitamins: Fundamental Aspects in Nutrition and Health, 3rd ed. Elsevier Academic Press, Burlington; 2008
Clarkson PM. Antioxidants and physical performance. Crit Rev Food Sci Nutr 1995; 35:131–141
Maxwell SR. Prospects for the use of antioxidant therapies. Drugs 1995; 49:345–361
Matill HA. Antioxidants. Annu Rev Biochem 1947; 16:177–192
Wolf G. Discovery of vitamin A. Encyclopedia of Life Sciences: Available at: http://www.mrw.interscience.wiley.com/emrw/9780470015902/els/article/a0003419/current/html; 2001
McCollum EV, Davis M. The necessity of certain lipins in the diet during growth. J Biol Chem 1913; 15:167–175
Osborne TB, Mendel LB. The relation of growth to the chemical constituents of the diet. J Biol Chem 1913; 15:311–326
Groff JL. Advanced Nutrition and Human Metabolism, 2nd ed. St Paul: West Publishing; 1995
Food and Nutrition Board Institute of Medicine. Vitamin A. Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc. National Academy Press, Washington DC; 2001
de Pee S, West CE. Dietary carotenoids and their role in combating vitamin A deficiency: a review of the literature. Eur J Clin Nutr 1996; 50(Suppl 3):S38–S53
Olson JA. Benefits and liabilities of vitamin A and carotenoids. J Nutr 1996; 126:1208S–1212S
Olson JA, Kobayashi S. Antioxidants in health and disease: overview. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine. New York, NY, 1992; 200:245–247
Paiva SA, Russell RM. Beta-carotene and other carotenoids as antioxidants. J Am Coll Nutr 1999; 18:426–433
Sato Y, Meller R, Yang T, et al. Stereo-selective neuroprotection against stroke with vitamin A derivatives. Brain Research 2008; 1241:188–192
Malaspina A, Michael-Titus AT. Is the modulation of retinoid and retinoid-associated signaling a future therapeutic strategy in neurological trauma and neurodegeneration? J Neurochem 2008; 104:584–595
McCaffery P, Drager DC. High level of a retinoic acid-generating dehydrogenase in the meso telencephalic dopamine system. Proc Natl Acad Sci USA 1994; 91:7772–7776
Nau H, Chahoud I, Dencker L, et al. Teratogenicity of vitamin A and retinoids. In: Blomhoff R (ed) Vitamin A in Health and Disease. Dekker, New York; 1994: 615–663
Satre MA, Ugen KE, Kochhar DM. Developmental changes in endogenous retinoids during pregnancy and embryogenesis in the mouse. Biol Reprod 1992; 46:802–810
Wagner E, Luo T, Drager UC. Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb Cortex 2002; 12:1244–1253
Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Hum Mol Genet 1997; 6:577–582
Balmer JE, Blomhoff R. Gene expression regulation by retinoic acid. J Lipid Res 2002; 43:1773–1808
Krezel W, Ghyselinck N, Samad TA, et al. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998; 279:863–867
Samad TA, Krezel W, Chambon P, Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proc Natl Acad Sci USA 1997; 94:14349–14354
Goodman AB. Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc Natl Acad Sci USA 1998; 95:7240–7244
Goodman AB. Microarray results suggest altered transport and lowered synthesis of retinoic acid in schizophrenia. Mol Psychiatry 2005; 10:620–621
Etchamendy N, Enderlin V, Marighetto A, et al. Vitamin A deficiency and relational memory deficit in adult mice: relationships with changes in brain retinoid signalling. Behavioural Brain Res 2003; 145:37–49
Misner DL, Jacobs S, Shimizu Y, et al. Vitamin deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc Natl Acad Sci USA 2001; 98:11714–11719
Alfos S, Boucheron C, Pallet V, et al. A retinoic acid receptor antagonist suppresses brain retinoic acid receptor overexpression and reverses a working memory deficit induced by chronic ethanol consumption in mice. Alcoholism, Clin Experimental Res 2001; 25:1506–1514
Corcoran JP, So PL, Maden M. Disruption of the retinoid signalling pathway causes a deposition of amyloid beta in the adult rat brain. Eur J Neurosci 2004; 20:896–902
Goodman AB, Pardee AB. Evidence for defective retinoid transport and function in late onset Alzheimer’s disease. Proc Natl Acad Sci USA 2003; 100:2901–2905
Lane MA, Bailey SJ. Role of retinoid signalling in the adult brain. Prog Neurobiol 2005; 75:275–293
Mey J, McCaffery P. Retinoic acid signaling in the nervous system of adult vertebrates. Neuroscientist 2004; 10:409–421
Lerner V, Miodownik C, Gibel A, et al. Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trial. Clinical Neuropharmacol 2008; 31:25–33
Wang HX, Wahlin A, Basun H, et al. Vitamin B(12) and folate in relation to the development of Alzheimer’s disease. Neurology 2001; 56:1188–1194
McDowell I. Alzheimer’s disease: insights from epidemiology. Aging (Milan, Italy) 2001; 13:143–162
Mahan LK, Escott-Stump S (eds) Krause’s food, nutrition, and diet therapy, 10th ed. W.B. Saunders Company, Philadelphia; 2000
McCollum EV. A History of Nutrition. Riverside Press, Houghton Mifflin, Cambridge, MA; 1957
Tanphaichitr V. Thiamin. In: Shils M, Olson JA, Shike M, Ross AC (eds) Modern Nutrition in Health and Disease, 9th ed. Williams & Wilkins, Baltimore; 1999: 381–389
Rodriguez-Martin JL, Qizilbash N, Lopez-Arrieta JM. Thiamine for Alzheimer’s disease. Cochrane database of systematic reviews (Online) 2001:CD001498
Barness LA, Tomarelli RM. Paul Gyorgy (1893–1976). A biographical sketch. J Nutr 1979; 109:19–23
Henderson L, Hulse J. Vitamin B6: Relationship to tryptophan metabolism. Human Vitamin B6 Requirements: proceedings of a workshop. National Academy of Sciences, Washington, DC; 1978:21–36
Roman GC. Nutritional disorders of the nervous system. In: Shils ME (ed) Modern Nutrition in Health and Disease, 10th ed. Lippincott Williams & Wilkins, Baltimore; 2006:1363–1380
Sauberlich HE. Vitamin B-6 (pyridoxine). In: Sauberlich HE (ed) Laboratory Tests for the Assessment of Nutritional Status, 2nd ed. CRC Press, Boca Raton; 1999
Clayton PT. B(6)-responsive disorders: A model of vitamin dependency. J Inherit Metab Dis 2006; 29:317–326
Rimland B, Callaway E, Dreyfus P. The effect of high doses of vitamin B6 on autistic children: a double-blind crossover study. Am J Psychiatry 1978; 135:472–475
Lelord G, Muh JP, Barthelemy C, et al. Effects of pyridoxine and magnesium on autistic symptoms – initial observations. J Autism Dev Disord 1981; 11:219–230
Martineau J, Barthelemy C, Lelord G. Long-term effects of combined vitamin B6-magnesium administration in an autistic child. Biol Psychiatry 1986; 21:511–518
Martineau J, Barthelemy C, Garreau B, Lelord G. Vitamin B6, magnesium, and combined B6-Mg: therapeutic effects in childhood autism. Biol Psychiatry 1985; 20:467–478
Agbayewa MO, Bruce VM, Siemens V. Pyridoxine, ascorbic acid and thiamine in Alzheimer and comparison subjects. Can J Psychiatry Revue Canadienne De Psychiatrie 1992; 37:661–662
Colgan M, Colgan L. Do nutrient supplements and dietary changes affect learning and emotional reactions of children with learning difficulties? A controlled series of 16 cases. Nutrition Health 1984; 3:69–77
Frye PE, Arnold LE. Persistent amphetamine-induced compulsive rituals: response to pyridoxine(B6). Biol Psychiatry 1981; 16:583–587
Emmanuel NP, Lydiard RB, Reynolds RD, et al. Plasma pyridoxal phosphate in anxiety disorders. Biol Psychiatry 1994; 36:606–608
Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ 1999; 318:1375–1381
Bucci L. Pyridoxine and schizophrenia. Br J Psychiatry 1973; 122:240
Brooks SC, D’Angelo L, Chalmeta A, et al. An unusual schizophrenic illness responsive to pyridoxine HCl (B6) subsequent to phenothiazine and butyrophenone toxicities. Biol Psychiatry 1983; 18:1321–1328
DeVeaugh-Geiss J, Manion L. High-dose pyridoxine in tardive dyskinesia. J Clin Psychiatry 1978; 39:573–575
Tkacz C. A preventive measure for tardive dyskinesia [letter]. J Int Acad Preventive Med 1984; 8:5
Devaux A. Dyskinesies tardives: role de la pyridoxine dans la prevention. Semin Hop Paris 1987; 63:1476–1480
Sandyk R, Pardeshi, R. Pyridoxine improves drug-induced parkinsonism and psychosis in a schizophrenic patient. Int J Neurosci 1990; 52(3–4):225–232
Bauernfeid JC, Miller ON. Vitamin B6: nutritional and pharmaceutical usage, stability, bioavailability, antagonists, and safety. Human Vitamin B6 Requirements: proceedings of a workshop. National Academy of Sciences, Washington, DC; 1978: 78–110
US Department of Agriculture Agricultural Research Service. USDA Nutrient Database for Standard Reference, Release 16. Nutrient Data Laboratory Home Page Available at: http://www.nal.usda.gov/fnic/cgi-bin/nut_search.pl; 2003
Pfeiffer CC. Mental and Elemental Nutrients. Keats Publishing, Inc., New Canaan, CT; 1975
Marks J. A Guide to the Vitamins: Their Role in Health and Disease. MRP Medical and Technical Publishing Co. Ltd, London; 1979
Braestrup C, Nielsen M. Anxiety. Lancet 1982; 2:1030–1034
Morani AS, Bodhankar SL. Neuroprotective effect of pyridoxine hydrochloride in models of mononeuropathy in rats. Pharmacology on-line 2007; 2:147–157
Dakshinamurti K, Sharma SK, Geiger JD. Neuroprotective actions of pyridoxine. Biochim Biophys Acta 2003; 1647:225–229
Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and “schizophrenia”. A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Engl J Med 1975; 292:491–496
Petrie WM, Ban TA, Ananth JV. The use of nicotinic acid and pyridoxine in the treatment of schizophrenia. Int Pharmacopsychiatry 1981; 16:245–250
Lerner V, Liberman M. Movement disorders and psychotic symptoms treated with pyridoxine: a case report [letter]. J Clin Psychiatry 1998; 59:623–624
Ananth JV, Ban TA, Lehmann HE. Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. Can Psychiatr Assoc J 1973; 18:377–383
Ban TA, Lehmann HE, Deutsch M. Negative findings with megavitamins in schizophrenic patients: preliminary report. Communications In Psychopharmacology 1977; 1:119–122
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study. J Clin Psychiatry 2002; 63:54–58
Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin b(6) treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65:1550–1554
Miodownik C, Lerner V, Statsenko N, et al. Vitamin B6 versus mianserin and placebo in acute neuroleptic-induced akathisia: a randomized, double-blind, controlled study. Clin Neuropharmacol 2006; 29:68–72
Wei IL, Huang YH, Wang GS. Vitamin B6 deficiency decreases the glucose utilization in cognitive brain structures of rats. J Nutr Biochem 1999; 10:525–531
Guilarte TR. Vitamin B6 and cognitive development: recent research findings from human and animal studies. Nutr Rev 1993; 51:193–198
Mulder C, Scheltens P, Barkhof F, et al. Low vitamin B6 levels are associated with white matter lesions in Alzheimer’s disease. J Am Geriatr Soc 2005; 53:1073–1074
Malouf R, Grimley Evans J. The effect of vitamin B6 on cognition. Cochrane Database Syst Rev 2003:CD004393
Selhub J, Bagley LC, Miller J, Rosenberg IH. B vitamins, homocysteine, and neurocognitive function in the elderly. Am J Clin Nutr 2000; 71:614S–620S
Riggs KM, Spiro A 3rd, Tucker K, Rush D. Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr 1996; 63:306–314
Sandyk R. L-tryptophan in neuropsychiatric disorders: a review. Int J Neurosci 1992; 67:127–144
Burke RE. Tardive dyskinesia: current clinical issues. Neurology 1984; 34:1348–1353
Cummings JL, Wirshing WC. Recognition and differential diagnosis of tardive dyskinesia. Int J Psychiatry Med 1989; 19:133–144
Klawans H. Recognition and diagnosis of tardive dyskinesia. J Clin Psychiatry 1985; 46:3–7
Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003; 9:16–27
Sachdev PS. The current status of tardive dyskinesia. Aust NZ J Psychiatry 2000; 34:355–369
Tarsy D. History and definition of tardive dyskinesia. Clin Neuropharmacol 1983; 6:91–99
Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992; 7:53–57
Chouinard G. New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 2004; 65(Suppl 9):9–15
Storey E, Lloyd J. Tardive tremor. Mov Dis 1997; 12:808–810
Kane JM. Tardive Dyskinesia. In: Jeste DV, Wyatt RJ (eds) Neuropsychiatric Movement Disorders. American Psychiatric Press, Washington, DC; 1984: 68–95
Jeste DV, Caliguiri MP. Tardive dyskinesia. Schizophr Bull 1993; 19:303–315
Kane JM, Woerner M, Lieberman J. Tardive dyskinesia. Prevalence, incidence and risk factor. J Clin Psychopharmacol 1988; 8:52–56
Barnes TR, McPhillips MA. Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia. Int Clin Psychopharmacol 1998; 13(Suppl 3):S49–S57
Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63(Suppl 4):12–19
Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiatry 2000; 61(Suppl 4):21–26
Silberbauer C. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 1998; 31:68–69
Ananth J, Kenan J. Tardive dyskinesia associated with olanzapine monotherapy. J Clin Psychiatry 1999; 60:870
Ghelber D, Belmaker RH. Tardive dyskinesia with quetiapine. Am J Psychiatry 1999; 156:796–797
Herran A, Vazquez-Barquero JL. Tardive dyskinesia associated with olanzapine. Ann Intern Med 1999; 131:72
Molho ES, Factor SA. Possible tardive dystonia resulting from clozapine therapy. Mov Disord 1999; 14:873–874
Bassitt DP, de Souza Lobo Garcia L. Risperidone-induced tardive dyskinesia. Pharmacopsychiatry 2000; 33:155–156
Bella VL, Piccoli F. Olanzapine-induced tardive dyskinesia. Br J Psychiatry 2003; 182:81–82
Ananth J, Burgoyne KS, Niz D, Smith M. Tardive dyskinesia in 2 patients treated with ziprasidone. J Psychiatry Neurosci 2004; 29:467–469
Keck ME, Muller MB, Binder EB, et al. Ziprasidone-related tardive dyskinesia. Am J Psychiatry 2004; 161:175–176
Ertugrul A, Demir B. Clozapine-induced tardive dyskinesia: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29:633–635
Soares KV, McGrath JJ. The treatment of tardive dyskinesia–a systematic review and meta-analysis. Schizophr Res 1999; 39:1–16
Dakshinamurti K, Paulose CS, Viswanathan M, et al. Neurobiology of pyridoxine. Ann NY Acad Sci 1990; 585:128–144
Schaeffer MC, Cochary EF, Sadowski JA. Subtle abnormalities of gait detected early in vitamin B6 deficiency in aged and weanling rats with hind leg gait analysis. J Am Coll Nutr 1990; 9:120–127
Paulson GW. Use of pyridoxine in chorea. [letter]. Am J Psychiatry 1971; 127:1091
Lerner V, Kaptsan A, Miodownik C, Kotler M. Vitamin B6 in treatment of tardive dyskinesia: a preliminary case series study. Clin Neuropharmacol 1999; 22:241–243
Miodownik C, Witztum E, Lerner V. Lithium-induced tremor treated with vitamin B6: a preliminary case series. Int J Psychiatry Med 2002; 32:103–108
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001; 158:1511–1514
Lerner V, Bergman J, Statsenko N, Miodownik C. Vitamin B6 treatment in acute neuroleptic-induced akathisia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2004; 65:1550–1554
Lerner V, Miodownik C, Kaptsan A, et al. Vitamin B6 treatment for tardive dyskinesia: A randomized double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007; 68: 11:1648–1654
Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672–676
Burton K. The treatment of tremor. Med J Australia 1987; 147:503–506
Kane J, Rifkin A, Quitkin F, Klein DF. Extrapyramidal side effects with lithium treatment. Am J Psychiatry 1978; 135:851–853
Tyrer P, Alexander MS, Regan A, Lee I. An extrapyramidal syndrome after lithium therapy. Br J Psychiatry 1980; 136:191–194
Tyrer P, Lee I, Trotter C. Physiological characteristics of tremor after chronic lithium therapy. Br J Psychiatry 1981; 139:59–61
Kamen B. Folate and antifolate pharmacology. Seminars Oncol 1997; 24:S18–30–S18–39
Fenech M, Aitken C, Rinaldi J. Folate, vitamin B12, homocysteine status and DNA damage in young Australian adults. Carcinogenesis 1998; 19:1163–1171
Bottiglieri T. Folate, vitamin B12, and neuropsychiatric disorders. Nutr Rev 1996; 54:382–390
Bottiglieri T, Hyland K, Laundy M, et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992; 22:871–876
Hutto BR. Folate and cobalamin in psychiatric illness. Compr Psychiatry 1997; 38:305–314
Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. BMJ 1998; 316:894–898
Brouwer IA, van Dusseldorp M, Duran M, et al. Low-dose folic acid supplementation does not influence plasma methionine concentrations in young non-pregnant women. Br J Nutr 1999; 82:85–89
Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol 2001; 113:579–589
Mitchell HK, Snell EE, Williams RJ. The concentration of “folic acid”. J Am Chem Soc 1941; 63:2284
Dietrich M, Brown CJ, Block G. The effect of folate fortification of cereal-grain products on blood folate status, dietary folate intake, and dietary folate sources among adult non-supplement users in the United States. J Am Coll Nutr 2005; 24:266–274
Suitor CW, Bailey LB. Dietary folate equivalents: interpretation and application. J Am Diet Association 2000; 100:88–94
Coppen A, Bolander-Gouaille C. Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacology (Oxford, England) 2005; 19:59–65
Taylor MJ, Carney SM, Goodwin GM, Geddes JR. Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacology (Oxford, England) 2004; 18:251–256
Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: a HuGE review. Am J Epidemiol 2007; 165:1–13
Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 2007; 61:631–637
Reynolds EH. Folic acid, ageing, depression, and dementia. BMJ 2002; 324:1512–1515
Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet 2007; 369:208–216
Tettamanti M, Garri MT, Nobili A, et al. Low folate and the risk of cognitive and functional deficits in the very old: the Monzino 80-plus study. J Am Coll Nutr 2006; 25:502–508
Schneider JA, Tangney CC, Morris MC. Folic acid and cognition in older persons. Exp Opin Drug Safety 2006; 5:511–522
Zhang X, Chen S, Li L, et al. Folic acid protects motor neurons against the increased homocysteine, inflammation and apoptosis in SOD1 G93A transgenic mice. Neuropharmacology 2008; 54:1112–1119
Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr 2004; 80:114–122
Berk M, Sanders KM, Pasco JA, et al. Vitamin D deficiency may play a role in depression. Med Hypotheses 2007; 69:1316–1319
Dogan M, Ozdemir O, Sal EA, et al. Psychotic disorder and extrapyramidal symptoms associated with vitamin B12 and folate deficiency. J Tropical Pediatrics 2009; 55:205–207
Stuerenburg HJ, Mueller-Thomsen T, Methner A. Vitamin B 12 plasma concentrations in Alzheimer disease. Neuro Endocrinol Lett 2004; 25:176–177
Green R, Miller J. Vitamin B12. In: Zempleni J, Rucker RB, McCormick DB, Suttie JW (eds) Handbook of Vitamins. CRC Press, Boca Raton; 2007: 413–488
Doscherholmen A, McMahon J, Ripley D. Vitamin B12 absorption from eggs. Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine. New York, NY 1975; 149:987–990
Akaike A, Tamura Y, Sato Y, Yokota T. Protective effects of a vitamin B12 analog, methylcobalamin, against glutamate cytotoxicity in cultured cortical neurons. Eur J Pharmacol 1993; 241:1–6
Garrison RJ, Somer E. The Nutrition Desk Reference. Keats Publishing, Inc., New Canaan, CT; 1998
Lerner V, Kanevsky M, Dwolatzky T, et al. Vitamin B12 and folate serum levels in newly admitted psychiatric patients. Clin Nutr (Edinburgh, Scotland) 2006; 25:60–67
Calvaresi E, Bryan J. B vitamins, cognition, and aging: a review. J Gerontology 2001; 56:P327–P339
Kim J-S, Sohn YH, Shin H-W. Vitamin B12 and homocysteine in relation to the cognitive dysfunction in Alzheimer’s and Parkinson’s disease. Alzheimer’s and Dementia 2006; 2(Suppl 1):254–255
Nilsson K, Gustafson L, Hultberg B. Improvement of cognitive functions after cobalamin/folate supplementation in elderly patients with dementia and elevated plasma homocysteine. Int Geriatr Psychiatry 2001; 16:609–614
Cooper JR. The role of ascorbic acid in the oxidation of tryptophan to 5-hydroxytryptophan. Ann NY Acad Sci 1961; 92:208–211
Waugh WA, King CG. Isolation and identification of vitamin C. J Biol Chem 1932; 97:325–331
Szent-Gyorgyi A. Studies on Biological Oxidation and Some of Its Catalysts. Szeged; 1937
Stone I. The Healing Factor: Vitamin C against Disease. Grosset & Dunlap; 1972
Carr AC, Frei B. Toward a new recommended dietary allowance for vitamin C based on antioxidant and health effects in humans. Am J Clin Nutr 1999; 69:1086–1107
Johnston CS, Steinberg FM, Rucker RB. Ascorbic Acid. In: Zempleni J, Rucker RB, McCormick DB, Suttie JW (eds) Handbook of Vitamins. CRC Press, Boca Raton, FL; 2007:489–520
Yokoyama T, Date C, Kokubo Y, et al. Serum vitamin C concentration was inversely associated with subsequent 20-year incidence of stroke in a Japanese rural community. The Shibata study. Stroke; J Cerebral Circulation 2000; 31:2287–2294
Myint PK, Luben RN, Welch AA, et al. Plasma vitamin C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the European Prospective Investigation into Cancer Norfolk prospective population study. Am J Clin Nutr 2008; 87:64–69
Santos LF, Freitas RL, Xavier SM, et al. Neuroprotective actions of vitamin C related to decreased lipid peroxidation and increased catalase activity in adult rats after pilocarpine-induced seizures. Pharmacol Biochem Behavior 2008; 89:1–5
Horwitt MK. Ascorbic acid requirements of individuals in a large institution. Proc Soc Exp Biol Med 1942; 49:248–250
Rebec GV, Centore JM, White LK, Alloway KD. Ascorbic acid and the behavioral response to haloperidol: implications for the action of antipsychotic drugs. Science 1985; 227:438–440
Singh RB, Ghosh S, Niaz MA, et al. Dietary intake, plasma levels of antioxidant vitamins, and oxidative stress in relation to coronary artery disease in elderly subjects. Am J Cardiol 1995; 76:1233–1238
Suboticanec K. Vitamin C status in schizophrenia. Bibliotheca nutritio et dieta 1986:173–181
Suboticanec K, Folnegovic-Smalc V, Korbar M, et al. Vitamin C status in chronic schizophrenia. Biol Psychiatry 1990; 28:959–966
Milner G. Ascorbic acid in chronic psychiatric patients: a controlled trial. Br J Psychiatry 1963; 109:294–299
Beauclair L, Vinogradov S, Riney SJ, et al. An adjunctive role for ascorbic acid in the treatment of schizophrenia? J Clin Psychopharmacol 1987; 7:282–283
Sandyk R, Kanofsky JD. Vitamin C in the treatment of schizophrenia. Int J Neurosci 1993; 68:67–71
Smythies JR. The role of ascorbate in brain: therapeutic implications. J Royal Soc Med 1996; 89:241
Dakhale GN, Khanzode SD, Khanzode SS, Saoji A. Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia. Psychopharmacology (Berl) 2005; 182:494–498
Arvindakshan M, Ghate M, Ranjekar PK, et al. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res 2003; 62:195–204
Riviere S, Birlouez-Aragon I, Nourhashemi F, Vellas B. Low plasma vitamin C in Alzheimer patients despite an adequate diet. Int J Geriatr Psychiatry 1998; 13:749–754
Gray SL, Hanlon JT, Landerman LR, et al. Is antioxidant use protective of cognitive function in the community-dwelling elderly? Am J Geriatr Pharmacother 2003; 1:3–10
Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61:82–88
Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 2002; 287:3223–3229
Naylor GJ. Vanadium and manic depressive psychosis. Nutr Health 1984; 3:79–85
Brody S. High-dose ascorbic acid increases intercourse frequency and improves mood: a randomized controlled clinical trial. Biol Psychiatry 2002; 52:371–374
Dolske MC, Spollen J, McKay S, et al. A preliminary trial of ascorbic acid as supplemental therapy for autism. Prog Neuropsychopharmacol Biol Psychiatry 1993; 17:765–774
Joshi K, Lad S, Kale M, et al. Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukot Essent Fatty Acids 2006; 74:17–21
Thiel R, Fowkes SW. Can cognitive deterioration associated with Down syndrome be reduced? Med Hypotheses 2005; 64:524–532
Rimland B. Has vitamin C been used in the treatment of autism? Autism Research Rev Int 1998; 12:3
Replogle WH, Eicke FJ. Megavitamin therapy in the reduction of anxiety and depression among alcoholics. J Orthomolec Med 1988; 4:221–224
Norman AW, Henry HL. Vitamin D. In: Zempleni J, Rucker RB, McCormick DB, Suttie JW (eds) Handbook of Vitamins. CRC Press, Boca Raton, FL; 2007
Brewer LD, Thibault V, Chen KC, et al. Vitamin D hormone confers neuroprotection in parallel with downregulation of L-type calcium channel expression in hippocampal neurons. J Neurosci 2001; 21:98–108
Kalueff AV, Eremin KO, Tuohimaa P. Mechanisms of neuroprotective action of vitamin D(3). Biochemistry 2004; 69:738–741
Mackay-Sim A, Feron F, Eyles D, et al. Schizophrenia, vitamin D, and brain development. Int Rev Neurobiol 2004; 59:351–380
McGrath J. Hypothesis: is low prenatal vitamin D a risk-modifying factor for schizophrenia? Schizophr Res 1999; 40:173–177
Schneider B, Weber B, Frensch A, et al. Vitamin D in schizophrenia, major depression and alcoholism. J Neural Transm 2000; 107:839–842
Yan J, Feng J, Craddock N, et al. Vitamin D receptor variants in 192 patients with schizophrenia and other psychiatric diseases. Neuroscience Lett 2005; 380:37–41
Anonymus. The Ebers Papyrus. Academy of Scientific Research, Cairo; 1987
Scott BO. The history of ultraviolet therapy. In: Licht S (ed) Therapeutic Electricity and Ultraviolet Radiation Physical Medicine Library. Elizabeth Licht, CT; 1967:196
Mozolowski W, Sniadecki J. On the cure of rickets. Nature 1939; 143:121
Mohr SB. A brief history of vitamin d and cancer prevention. Ann Epidemiol 2009; 19:79–83
Carpenter KJ, Zhao L. Forgotten mysteries in the early history of vitamin D. J Nutr 1999; 129:923–927
National Institutes of Health. Office of Dietary Supplements. Available at: http://ods.od.nih.gov/factsheets/vitamind.asp; 2008
McGrath J, Saari K, Hakko H, et al. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr Res 2004; 67:237–245
Becker A, Eyles DW, McGrath JJ, Grecksch G. Transient prenatal vitamin D deficiency is associated with subtle alterations in learning and memory functions in adult rats. Behav Brain Res 2005; 161:306–312
Garcion E, Wion-Barbot N, Montero-Menei CN, et al. New clues about vitamin D functions in the nervous system. Trends in endocrinology and metabolism: TEM 2002; 13:100–105
Kiraly SJ, Kiraly MA, Hawe RD, Makhani N. Vitamin D as a neuroactive substance: review. Sci World J 2006; 6:125–139
Llewellyn DJ, Langa K, Lang I. Serum 25-Hydroxyvitamin D Concentration and Cognitive Impairment. J Geriatric Psychiatry Neurol 2009
Wilkins CH, Sheline YI, Roe CM, et al. Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry 2006; 14:1032–1040
Armstrong DJ, Meenagh GK, Bickle I, et al. Vitamin D deficiency is associated with anxiety and depression in fibromyalgia. Clin Rheumatol 2007; 26:551–554
Grant WB. Does vitamin D reduce the risk of dementia? J Alzheimers Dis 2009; 17:151–159
Traber MG, Atkinson J. Vitamin E, antioxidant and nothing more. Free Radical Biol Med 2007; 43:4–15
Wang X, Quinn PJ. Vitamin E and its function in membranes. Progress Lipid Res 1999; 38:309–336
Brigelius-Flohe R, Davies KJ. Is vitamin E an antioxidant, a regulator of signal transduction and gene expression, or a ‘junk’ food? Comments on the two accompanying papers: “Molecular mechanism of alpha-tocopherol action” by A. Azzi and “Vitamin E, antioxidant and nothing more” by M. Traber and J. Atkinson. Free Radical Biol Med 2007; 43:2–3
Atkinson J, Epand RF, Epand RM. Tocopherols and tocotrienols in membranes: a critical review. Free Radical Biol Med 2008; 44:739–764
Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. Curr Med Chem 2004; 11:1113–1133
Azzi A. Molecular mechanism of alpha-tocopherol action. Free Radical Biol Med 2007; 43:16–21
Kaput J, Ordovas JM, Ferguson L, et al. The case for strategic international alliances to harness nutritional genomics for public and personal health. Br J Nutr 2005; 94:623–632
D’Souza B, D’Souza V. Oxidative injury and antioxidant vitamins E and C in schizophrenia. Indian J Clin Biochem 2003; 18:87–90
Adler LA, Edson R, Lavori P, et al. Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 1998; 43:868–872
Adler LA, Peselow E, Rotrosen J, et al. Vitamin E treatment of tardive dyskinesia. Pm J Psychiatry 1993; 150:1405–1407
Adler LA, Rotrosen J, Edson R, et al. Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 1999; 56:836–841
Barak Y, Swartz M, Shamir E, et al. Vitamin E (alpha-tocopherol) in the treatment of tardive dyskinesia: a statistical meta-analysis. Ann Clin Psychiatry 1998; 10:101–105
Boomershine KH, Shelton PS, Boomershine JE. Vitamin E in the treatment of tardive dyskinesia. Ann Pharmacotherapy 1999; 33:1195–1202
Dannon PN, Grunhaus L, Iancu I, et al. Vitamin E treatment in tardive dystonia. Clin Neuropharmacol 1997; 20:434–437
Dorevitch A, Kalian M, Shlafman M, Lerner V. Treatment of long-term tardive dyskinesia with vitamin E. Biol Psychiatry 1997; 41:114–116
Egan MF, Hyde TM, Albers GW, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992; 149:773–777
Gattaz WF. Does vitamin E prevent tardive dyskinesia? Biol Psychiatry 1995; 37:896–897
Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167–173
Sajjad SH. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. Int Clin Psychopharmacol 1998; 13:147–155
Shriqui CL, Bradwejn J, Annable L, Jones BD. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study. Am J Psychiatry 1992; 149:391–393
Soares KV, McGrath JJ. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane database of systematic reviews (Online) 2001:CD000209
Osakada F, Hashino A, Kume T, Katsuki H, Kaneko S, Akaike A. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. Neuropharmacology 2004; 47:904–915
Osakada F, Hashino A, Kume T, et al. Neuroprotective effects of alpha-tocopherol on oxidative stress in rat striatal cultures. Eur J Pharmacol 2003; 465:15–22
Roghani M, Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson’s disease in rat: behavioral and histochemical evidence. Brain Res 2001; 892:211–217
Post A, Rucker M, Ohl F, et al. Mechanisms underlying the protective potential of alpha-tocopherol (vitamin E) against haloperidol-associated neurotoxicity. Neuropsychopharmacology 2002; 26:397–407
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this chapter
Cite this chapter
Miodownik, C., Lerner, V. (2010). The Neuroprotective Efficacy of Vitamins. In: Ritsner, M. (eds) Brain Protection in Schizophrenia, Mood and Cognitive Disorders. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-8553-5_17
Download citation
DOI: https://doi.org/10.1007/978-90-481-8553-5_17
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-8552-8
Online ISBN: 978-90-481-8553-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)